LSTM Home > LSTM Research > LSTM Online Archive

Potential health impact and cost-effectiveness of drug therapy for prehypertension.

Downloads

Downloads per month over past year

Chen, Tao ORCID: https://orcid.org/0000-0002-5489-6450, Yu, Dahai, Cornelius, Victoria, Qin, Rui, Cai, Yamei, Jiang, Zhixin and Zhao, Zhanzheng (2017) 'Potential health impact and cost-effectiveness of drug therapy for prehypertension.'. International Journal of Cardiology, Vol 240, pp. 403-408.

[img]
Preview
Text
Int_J_Cardiology_Accepted_version_Chen_2017.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (732kB) | Preview
[img]
Preview
Text
Int_J_Cardiology_Accepted_version_Supplemental_Mat_Chen_2017.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

Studies have reported that pharmacologic interventions with candesartan or ramipril could reduce the risk of hypertension among prehypertensive subjects free of clinical cardiovascular disease (CVD), however, the cost-effectiveness and long-term cardiovascular risk of drug treatment among these population is unclear. A Markov state-transition model was developed to simulate a hypothetical cohort of Chinese adults with high-range prehypertension (130-139/85-89mmHg) but without CVD. Data on the incidence of CVD and hypertension was obtained from corresponding risk equations. Utility and disease-related costs were obtained from published literatures. Robustness and uncertainty was evaluated using deterministic and probabilistic sensitivity analyses. Compared with placebo, drug treatment resulted in delaying the development of hypertension by nearly 12years and reducing the absolute incidence of hypertension by 32.01% over lifetime. The cumulative incidence of coronary heart disease, stroke and heart failure were reduced and survival was improved from 28.46 to 28.80years. The average incremental cost effectiveness ratio for drug treatment was $12,994 per quality-adjusted life-year and the value was mostly sensitive to the effect size of treatment and age starting treatment. At a willingness-to-pay threshold of >3×China gross domestic product per capita in 2014, there was a 30.48% chance that drug treatment would remain cost-effective and a low chance of being cost-effective if relative risk of treatment on hypertension was larger than 0.64. Drug treatment for prehypertension may help stem the current epidemic of hypertension among Chinese adults free of CVD, which may in turn reduce CVD complications and potentially be cost effective.

Item Type: Article
Subjects: QV Pharmacology > Cardiovascular Agents. Renal Agents > QV 150 Cardiovascular agents
WA Public Health > WA 30 Socioeconomic factors in public health (General)
WG Cardiovascular System > WG 120 Cardiovascular diseases
WG Cardiovascular System > WG 20 Research (General)
Faculty: Department: Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI): https://doi.org/10.1016/j.ijcard.2017.05.003
SWORD Depositor: JISC Pubrouter
Depositing User: JISC Pubrouter
Date Deposited: 31 May 2017 13:18
Last Modified: 15 Jun 2018 14:04
URI: https://archive.lstmed.ac.uk/id/eprint/7157

Statistics

View details

Actions (login required)

Edit Item Edit Item